CD8A and Miyoshi myopathy: Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) increases CD8+ T-cell numbers, upregulates co-stimulatory molecules and reduce inhibitory checkpoint molecules in MM patients (244).